Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemvidutide DDI Study in Healthy Volunteers
NCT04972396Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemvidutide in obesity and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Altimmune, Inc. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve at Day 43. Started Sep 2021; status: completed.
02
Drugs
pemvidutide
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04972396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972396.